Clinical trial
Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer
NCT00003917 · Case Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003917 |
|---|---|
| Title | Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer |
| Official title | An Open Label, Multicenter, Randomized, Phase III Comparator Study of Oral Topotecan Versus Intravenous Topotecan for Second Line Therapy in Patients With Small Cell Lung Cancer Who Have Relapsed Greater Than or Equal to 90 Days After Completion of First Line Therapy |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Collaborators | Smith Kline Beecham |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | topotecan hydrochloride |
| Enrollment | 4 |
| Start date | Mar 1, 1999 |
| Primary completion | Nov 1, 2001 |
| Completion | Nov 1, 2001 |
| First posted | Apr 14, 2004 |
| Last update posted | Jan 9, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: